Geminin: a Biomarker with Significant Prognostic Potential in Cancer and Neuronal Differentiation

Summary A nuclear protein known as geminin is proposed as a broadly applicable cancer biomarker. The geminin protein was initially discovered by Kirchner et al. as an inhibitor of DNA synthesis and as a key regulator of genetic stability during chromosomal replication. Recent studies have pointed out a novel, and as of yet unelucidated, role for geminin as an oncogene. These studies have shown consistent upregulation of geminin in a variety of cancers, and have further suggested that geminin has significant clinical utility as both a cancer diagnostic and prognostic.

Applications Early applications of the geminin biomarker may focus on breast cancer and lymphoma prognosis. Companies with strong reagent libraries and cellular analysis systems may package Ki67 with geminin for immunohistochemistry-based (breast) and flow-cytometry (lymphoma) prognostics.

As an adjunct, geminin also has important research applications for tracking the cell cycle and the transition of proliferating neural progenitors into differentiating neurons (see Developmental Cell, Vol. 9, August, 2005). For Further Information Please Contact the Director of Business Development Michal Preminger Email: [email protected] Telephone: (617) 432-0920

Inventor(s): Kirschner, Marc W

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent